Sonoma Biotherapeutics
Eleonora Trotta is currently the Director at Sonoma Biotherapeutics. Prior to this, Eleonora held roles as the Associate Director and Principal Scientist at the same company. Before their time at Sonoma Biotherapeutics, Eleonora worked at PACT Pharma as the Principal Investigator Next Generation and Senior Scientist. Eleonora also gained experience as a Specialist at UCSF Medical Center and as a PostDoc at UCSF in collaboration with CTI-Pfizer. Eleonora completed their PhD in Immunological Sciences at the University of Rome "La Sapienza" and holds a Master's Degree in Medical, Molecular and Cellular Biotechnologies from the same institution. Eleonora also obtained a degree in Biotechnologies from the University of Rome "Tor Vergata".
This person is not in any offices
Sonoma Biotherapeutics
1 followers
Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.